Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer

NCT01625260 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.

NCT NCT01625260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01625260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer
Lead sponsor
Altor BioScience
Phase
Phase 1/2
Overall status
Terminated
Start date
March 30, 2012
Completion date
March 8, 2018
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer